enGene (ENGN) Stock: Buy, Sell, or Hold?
ENGN - enGene Holdings Inc. Common Stock
$1.80
0.03 (1.69%)
▲
5d:
-1.64%
30d:
+5.88%
90d:
+9.76%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Sep 10, 2026
0d
Get Alerted When ENGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ENGN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ENGN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ENGN is currently trading at $1.80, which is considered extended relative to its 30-day fair value range of $1.74 to $1.87.
Technical Outlook: Technically, ENGN is in a downtrend. The price is currently testing key support at $1.76. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ENGN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.29 (+82.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENGN is in a downtrend. The price is currently testing key support at $1.76. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ENGN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.29 (+82.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.74 -
$1.87
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 82.5% below Wall St target ($3.29)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.74 -
$1.87
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.76
Resistance Level
$1.94
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.25
Wall Street Target
$3.29
(+82.5%)
Share & Embed Analysis
Last updated: September 13, 2026 6:30 PM ET
Data refreshes hourly during market hours. Next update: 7:30 PM
Data refreshes hourly during market hours. Next update: 7:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
